Publikationen, an denen er mitarbeitet Rafael Arroyo González (29)

2024

  1. A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression

    Frontiers in Immunology, Vol. 15

  2. Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis

    International Journal of Molecular Sciences, Vol. 25, Núm. 18

2023

  1. Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response

    Frontiers in Immunology, Vol. 14

2022

  1. Epstein-Barr Virus Load Correlates with Multiple Sclerosis-Associated Retrovirus Envelope Expression

    Biomedicines, Vol. 10, Núm. 2

  2. Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study

    Frontiers in Immunology, Vol. 13

  3. Mitochondrial Impairments in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients

    Biology, Vol. 11, Núm. 11

2021

  1. Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression

    Frontiers in Immunology, Vol. 12

  2. Evolution of antibody titres against Epstein–Barr virus and human herpesvirus 6A/B and expression of multiple sclerosis-associated retrovirus in the serum of pregnant multiple sclerosis patients

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Acetate correlates with disability and immune response in multiple sclerosis

    PeerJ, Vol. 8

  2. MicroRNAs of Human Herpesvirus 6A and 6B in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients

    Frontiers in Immunology, Vol. 11

  3. Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab

    Scientific Reports, Vol. 10, Núm. 1

  4. Syncytin-1/HERV-W envelope is an early activation marker of leukocytes and is upregulated in multiple sclerosis patients

    European Journal of Immunology, Vol. 50, Núm. 5, pp. 685-694

2019

  1. Epidemiology of multiple sclerosis and vitamin D levels in Lanzarote, Canary Islands, Spain

    PeerJ, Vol. 2019, Núm. 12

2018

  1. Study of the possible link of 25-hydroxyvitamin D with Epstein–Barr virus and human herpesvirus 6 in patients with multiple sclerosis

    European Journal of Neurology, Vol. 25, Núm. 12, pp. 1446-1453

2017

  1. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort

    European Journal of Clinical Investigation, Vol. 47, Núm. 2, pp. 158-166

2016

  1. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients

    European Journal of Neurology, Vol. 23, Núm. 1, pp. 182-189

2014

  1. Anti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosis

    PLoS ONE, Vol. 9, Núm. 8

  2. HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV

    Retrovirology, Vol. 11, Núm. 1

  3. Toll-like receptor-9 in Spanish multiple sclerosis patients: An association with the gender

    European Journal of Neurology, Vol. 21, Núm. 3, pp. 537-540

2013

  1. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of spanish multiple sclerosis patients treated with natalizumab

    Journal of Neuroimmune Pharmacology, Vol. 8, Núm. 5, pp. 1277-1286